

## UGANDA Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

|   |               |               |               |                    |
|---|---------------|---------------|---------------|--------------------|
| <b>1. Country:</b> Uganda   |               |               |               |                    |
| <b>2. Grant number:</b> 1820-UGA-13b-X  |               |               |               |                    |
| <b>3. Date of Decision Letter:</b> 17 October 2017  |               |               |               |                    |
| <b>4. Date of the Partnership Framework Agreement:</b> 28 June 2013   |               |               |               |                    |
| <b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine   |               |               |               |                    |
| <b>6. Vaccine type:</b> Rotavirus   |               |               |               |                    |
| <b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule                              |               |               |               |                    |
| <b>8. Programme duration<sup>1</sup>:</b> 2018 – 2020   |               |               |               |                    |
| <b>9. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)           |               |               |               |                    |
|   | 2018          | 2019          | 2020          | Total <sup>2</sup> |
| Programme Budget (US\$)   | US\$7,728,000 | US\$6,508,500 | US\$6,863,500 | US\$21,100,000     |
| <b>10. Vaccine introduction grant (in US\$):</b> 1,506,500  |               |               |               |                    |
| <b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>3</sup> |               |               |               |                    |
| Type of supplies to be purchased with Gavi funds in each year   |               |               |               | 2018               |
| Number of Rotavirus vaccines doses  |               |               |               | 3,718,500          |
| Annual Amounts (US\$)   |               |               |               | US\$7,728,000      |
| <b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.                 |               |               |               |                    |
| <b>13. Self-procurement:</b> Not applicable   |               |               |               |                    |

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

**14. Co-financing obligations:** Reference code: 1820-UGA-13b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

| Type of supplies to be purchased with Country funds in each year | 2018        | 2019        | 2020        |
|--|-------------|-------------|-------------|
| Number of vaccine doses  | 397,500     | 334,500     | 352,500     |
| Value of vaccine doses (US\$)                                    | US\$797,098 | US\$671,317 | US\$707,919 |
| Total co-financing payments (US\$) (including freight)           | US\$823,500 | US\$693,500 | US\$731,500 |

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:**

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

| Reports and other information   | Due dates                     |
|---|-------------------------------|
| To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | May                           |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.   | To be agreed with Secretariat |

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

17 October 2017